Global Pulmonary Fibrosis Drug Market Research Report 2024(Status and Outlook)
Report Overview:
Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
The Global Pulmonary Fibrosis Drug Market Size was estimated at USD 4552.57 million in 2023 and is projected to reach USD 6100.89 million by 2029, exhibiting a CAGR of 5.00% during the forecast period.
This report provides a deep insight into the global Pulmonary Fibrosis Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pulmonary Fibrosis Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pulmonary Fibrosis Drug market in any manner.
Global Pulmonary Fibrosis Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Market Segmentation (by Type)
Pirfenidone
Nintedanib
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pulmonary Fibrosis Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
The Global Pulmonary Fibrosis Drug Market Size was estimated at USD 4552.57 million in 2023 and is projected to reach USD 6100.89 million by 2029, exhibiting a CAGR of 5.00% during the forecast period.
This report provides a deep insight into the global Pulmonary Fibrosis Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pulmonary Fibrosis Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pulmonary Fibrosis Drug market in any manner.
Global Pulmonary Fibrosis Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Market Segmentation (by Type)
Pirfenidone
Nintedanib
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Pulmonary Fibrosis Drug Market
- Overview of the regional outlook of the Pulmonary Fibrosis Drug Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pulmonary Fibrosis Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Pulmonary Fibrosis Drug
1.2 Key Market Segments
1.2.1 Pulmonary Fibrosis Drug Segment by Type
1.2.2 Pulmonary Fibrosis Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PULMONARY FIBROSIS DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Pulmonary Fibrosis Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PULMONARY FIBROSIS DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Pulmonary Fibrosis Drug Sales by Manufacturers (2019-2024)
3.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Pulmonary Fibrosis Drug Sales Sites, Area Served, Product Type
3.6 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
3.6.1 Pulmonary Fibrosis Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PULMONARY FIBROSIS DRUG INDUSTRY CHAIN ANALYSIS
4.1 Pulmonary Fibrosis Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PULMONARY FIBROSIS DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2019-2024)
6.3 Global Pulmonary Fibrosis Drug Market Size Market Share by Type (2019-2024)
6.4 Global Pulmonary Fibrosis Drug Price by Type (2019-2024)
7 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pulmonary Fibrosis Drug Market Sales by Application (2019-2024)
7.3 Global Pulmonary Fibrosis Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
8 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY REGION
8.1 Global Pulmonary Fibrosis Drug Sales by Region
8.1.1 Global Pulmonary Fibrosis Drug Sales by Region
8.1.2 Global Pulmonary Fibrosis Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Pulmonary Fibrosis Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pulmonary Fibrosis Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pulmonary Fibrosis Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pulmonary Fibrosis Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Boehringer Ingelheim
9.1.1 Boehringer Ingelheim Pulmonary Fibrosis Drug Basic Information
9.1.2 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Overview
9.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Market Performance
9.1.4 Boehringer Ingelheim Business Overview
9.1.5 Boehringer Ingelheim Pulmonary Fibrosis Drug SWOT Analysis
9.1.6 Boehringer Ingelheim Recent Developments
9.2 Roche
9.2.1 Roche Pulmonary Fibrosis Drug Basic Information
9.2.2 Roche Pulmonary Fibrosis Drug Product Overview
9.2.3 Roche Pulmonary Fibrosis Drug Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Pulmonary Fibrosis Drug SWOT Analysis
9.2.6 Roche Recent Developments
9.3 FibroGen, Inc.
9.3.1 FibroGen, Inc. Pulmonary Fibrosis Drug Basic Information
9.3.2 FibroGen, Inc. Pulmonary Fibrosis Drug Product Overview
9.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug SWOT Analysis
9.3.5 FibroGen, Inc. Business Overview
9.3.6 FibroGen, Inc. Recent Developments
9.4 Merck and Co., Inc.
9.4.1 Merck and Co., Inc. Pulmonary Fibrosis Drug Basic Information
9.4.2 Merck and Co., Inc. Pulmonary Fibrosis Drug Product Overview
9.4.3 Merck and Co., Inc. Pulmonary Fibrosis Drug Product Market Performance
9.4.4 Merck and Co., Inc. Business Overview
9.4.5 Merck and Co., Inc. Recent Developments
9.5 Bristol-Myers Squibb Company
9.5.1 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Basic Information
9.5.2 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Overview
9.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Market Performance
9.5.4 Bristol-Myers Squibb Company Business Overview
9.5.5 Bristol-Myers Squibb Company Recent Developments
9.6 MediciNova, Inc.
9.6.1 MediciNova, Inc. Pulmonary Fibrosis Drug Basic Information
9.6.2 MediciNova, Inc. Pulmonary Fibrosis Drug Product Overview
9.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.6.4 MediciNova, Inc. Business Overview
9.6.5 MediciNova, Inc. Recent Developments
9.7 Genentech, Inc.
9.7.1 Genentech, Inc. Pulmonary Fibrosis Drug Basic Information
9.7.2 Genentech, Inc. Pulmonary Fibrosis Drug Product Overview
9.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.7.4 Genentech, Inc. Business Overview
9.7.5 Genentech, Inc. Recent Developments
9.8 Cipla Inc.
9.8.1 Cipla Inc. Pulmonary Fibrosis Drug Basic Information
9.8.2 Cipla Inc. Pulmonary Fibrosis Drug Product Overview
9.8.3 Cipla Inc. Pulmonary Fibrosis Drug Product Market Performance
9.8.4 Cipla Inc. Business Overview
9.8.5 Cipla Inc. Recent Developments
9.9 Biogen
9.9.1 Biogen Pulmonary Fibrosis Drug Basic Information
9.9.2 Biogen Pulmonary Fibrosis Drug Product Overview
9.9.3 Biogen Pulmonary Fibrosis Drug Product Market Performance
9.9.4 Biogen Business Overview
9.9.5 Biogen Recent Developments
9.10 Galapagos NV
9.10.1 Galapagos NV Pulmonary Fibrosis Drug Basic Information
9.10.2 Galapagos NV Pulmonary Fibrosis Drug Product Overview
9.10.3 Galapagos NV Pulmonary Fibrosis Drug Product Market Performance
9.10.4 Galapagos NV Business Overview
9.10.5 Galapagos NV Recent Developments
10 PULMONARY FIBROSIS DRUG MARKET FORECAST BY REGION
10.1 Global Pulmonary Fibrosis Drug Market Size Forecast
10.2 Global Pulmonary Fibrosis Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Pulmonary Fibrosis Drug Market Size Forecast by Country
10.2.3 Asia Pacific Pulmonary Fibrosis Drug Market Size Forecast by Region
10.2.4 South America Pulmonary Fibrosis Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Pulmonary Fibrosis Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Pulmonary Fibrosis Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Type (2025-2030)
11.1.2 Global Pulmonary Fibrosis Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Pulmonary Fibrosis Drug by Type (2025-2030)
11.2 Global Pulmonary Fibrosis Drug Market Forecast by Application (2025-2030)
11.2.1 Global Pulmonary Fibrosis Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Pulmonary Fibrosis Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Pulmonary Fibrosis Drug
1.2 Key Market Segments
1.2.1 Pulmonary Fibrosis Drug Segment by Type
1.2.2 Pulmonary Fibrosis Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PULMONARY FIBROSIS DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Pulmonary Fibrosis Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PULMONARY FIBROSIS DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Pulmonary Fibrosis Drug Sales by Manufacturers (2019-2024)
3.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Pulmonary Fibrosis Drug Sales Sites, Area Served, Product Type
3.6 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
3.6.1 Pulmonary Fibrosis Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PULMONARY FIBROSIS DRUG INDUSTRY CHAIN ANALYSIS
4.1 Pulmonary Fibrosis Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PULMONARY FIBROSIS DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2019-2024)
6.3 Global Pulmonary Fibrosis Drug Market Size Market Share by Type (2019-2024)
6.4 Global Pulmonary Fibrosis Drug Price by Type (2019-2024)
7 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pulmonary Fibrosis Drug Market Sales by Application (2019-2024)
7.3 Global Pulmonary Fibrosis Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
8 PULMONARY FIBROSIS DRUG MARKET SEGMENTATION BY REGION
8.1 Global Pulmonary Fibrosis Drug Sales by Region
8.1.1 Global Pulmonary Fibrosis Drug Sales by Region
8.1.2 Global Pulmonary Fibrosis Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Pulmonary Fibrosis Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pulmonary Fibrosis Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pulmonary Fibrosis Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pulmonary Fibrosis Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Boehringer Ingelheim
9.1.1 Boehringer Ingelheim Pulmonary Fibrosis Drug Basic Information
9.1.2 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Overview
9.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Market Performance
9.1.4 Boehringer Ingelheim Business Overview
9.1.5 Boehringer Ingelheim Pulmonary Fibrosis Drug SWOT Analysis
9.1.6 Boehringer Ingelheim Recent Developments
9.2 Roche
9.2.1 Roche Pulmonary Fibrosis Drug Basic Information
9.2.2 Roche Pulmonary Fibrosis Drug Product Overview
9.2.3 Roche Pulmonary Fibrosis Drug Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Pulmonary Fibrosis Drug SWOT Analysis
9.2.6 Roche Recent Developments
9.3 FibroGen, Inc.
9.3.1 FibroGen, Inc. Pulmonary Fibrosis Drug Basic Information
9.3.2 FibroGen, Inc. Pulmonary Fibrosis Drug Product Overview
9.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug SWOT Analysis
9.3.5 FibroGen, Inc. Business Overview
9.3.6 FibroGen, Inc. Recent Developments
9.4 Merck and Co., Inc.
9.4.1 Merck and Co., Inc. Pulmonary Fibrosis Drug Basic Information
9.4.2 Merck and Co., Inc. Pulmonary Fibrosis Drug Product Overview
9.4.3 Merck and Co., Inc. Pulmonary Fibrosis Drug Product Market Performance
9.4.4 Merck and Co., Inc. Business Overview
9.4.5 Merck and Co., Inc. Recent Developments
9.5 Bristol-Myers Squibb Company
9.5.1 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Basic Information
9.5.2 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Overview
9.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Market Performance
9.5.4 Bristol-Myers Squibb Company Business Overview
9.5.5 Bristol-Myers Squibb Company Recent Developments
9.6 MediciNova, Inc.
9.6.1 MediciNova, Inc. Pulmonary Fibrosis Drug Basic Information
9.6.2 MediciNova, Inc. Pulmonary Fibrosis Drug Product Overview
9.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.6.4 MediciNova, Inc. Business Overview
9.6.5 MediciNova, Inc. Recent Developments
9.7 Genentech, Inc.
9.7.1 Genentech, Inc. Pulmonary Fibrosis Drug Basic Information
9.7.2 Genentech, Inc. Pulmonary Fibrosis Drug Product Overview
9.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Product Market Performance
9.7.4 Genentech, Inc. Business Overview
9.7.5 Genentech, Inc. Recent Developments
9.8 Cipla Inc.
9.8.1 Cipla Inc. Pulmonary Fibrosis Drug Basic Information
9.8.2 Cipla Inc. Pulmonary Fibrosis Drug Product Overview
9.8.3 Cipla Inc. Pulmonary Fibrosis Drug Product Market Performance
9.8.4 Cipla Inc. Business Overview
9.8.5 Cipla Inc. Recent Developments
9.9 Biogen
9.9.1 Biogen Pulmonary Fibrosis Drug Basic Information
9.9.2 Biogen Pulmonary Fibrosis Drug Product Overview
9.9.3 Biogen Pulmonary Fibrosis Drug Product Market Performance
9.9.4 Biogen Business Overview
9.9.5 Biogen Recent Developments
9.10 Galapagos NV
9.10.1 Galapagos NV Pulmonary Fibrosis Drug Basic Information
9.10.2 Galapagos NV Pulmonary Fibrosis Drug Product Overview
9.10.3 Galapagos NV Pulmonary Fibrosis Drug Product Market Performance
9.10.4 Galapagos NV Business Overview
9.10.5 Galapagos NV Recent Developments
10 PULMONARY FIBROSIS DRUG MARKET FORECAST BY REGION
10.1 Global Pulmonary Fibrosis Drug Market Size Forecast
10.2 Global Pulmonary Fibrosis Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Pulmonary Fibrosis Drug Market Size Forecast by Country
10.2.3 Asia Pacific Pulmonary Fibrosis Drug Market Size Forecast by Region
10.2.4 South America Pulmonary Fibrosis Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Pulmonary Fibrosis Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Pulmonary Fibrosis Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Type (2025-2030)
11.1.2 Global Pulmonary Fibrosis Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Pulmonary Fibrosis Drug by Type (2025-2030)
11.2 Global Pulmonary Fibrosis Drug Market Forecast by Application (2025-2030)
11.2.1 Global Pulmonary Fibrosis Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Pulmonary Fibrosis Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pulmonary Fibrosis Drug Market Size Comparison by Region (M USD)
Table 5. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Pulmonary Fibrosis Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 10. Global Market Pulmonary Fibrosis Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Pulmonary Fibrosis Drug Sales Sites and Area Served
Table 12. Manufacturers Pulmonary Fibrosis Drug Product Type
Table 13. Global Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pulmonary Fibrosis Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pulmonary Fibrosis Drug Market Challenges
Table 22. Global Pulmonary Fibrosis Drug Sales by Type (Kilotons)
Table 23. Global Pulmonary Fibrosis Drug Market Size by Type (M USD)
Table 24. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2019-2024)
Table 26. Global Pulmonary Fibrosis Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Pulmonary Fibrosis Drug Market Size Share by Type (2019-2024)
Table 28. Global Pulmonary Fibrosis Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Application
Table 30. Global Pulmonary Fibrosis Drug Market Size by Application
Table 31. Global Pulmonary Fibrosis Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2019-2024)
Table 33. Global Pulmonary Fibrosis Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Pulmonary Fibrosis Drug Market Share by Application (2019-2024)
Table 35. Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2019-2024)
Table 38. North America Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. Boehringer Ingelheim Pulmonary Fibrosis Drug Basic Information
Table 44. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Overview
Table 45. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Boehringer Ingelheim Business Overview
Table 47. Boehringer Ingelheim Pulmonary Fibrosis Drug SWOT Analysis
Table 48. Boehringer Ingelheim Recent Developments
Table 49. Roche Pulmonary Fibrosis Drug Basic Information
Table 50. Roche Pulmonary Fibrosis Drug Product Overview
Table 51. Roche Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Roche Business Overview
Table 53. Roche Pulmonary Fibrosis Drug SWOT Analysis
Table 54. Roche Recent Developments
Table 55. FibroGen, Inc. Pulmonary Fibrosis Drug Basic Information
Table 56. FibroGen, Inc. Pulmonary Fibrosis Drug Product Overview
Table 57. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. FibroGen, Inc. Pulmonary Fibrosis Drug SWOT Analysis
Table 59. FibroGen, Inc. Business Overview
Table 60. FibroGen, Inc. Recent Developments
Table 61. Merck and Co., Inc. Pulmonary Fibrosis Drug Basic Information
Table 62. Merck and Co., Inc. Pulmonary Fibrosis Drug Product Overview
Table 63. Merck and Co., Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Merck and Co., Inc. Business Overview
Table 65. Merck and Co., Inc. Recent Developments
Table 66. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Basic Information
Table 67. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Overview
Table 68. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Bristol-Myers Squibb Company Business Overview
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. MediciNova, Inc. Pulmonary Fibrosis Drug Basic Information
Table 72. MediciNova, Inc. Pulmonary Fibrosis Drug Product Overview
Table 73. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. MediciNova, Inc. Business Overview
Table 75. MediciNova, Inc. Recent Developments
Table 76. Genentech, Inc. Pulmonary Fibrosis Drug Basic Information
Table 77. Genentech, Inc. Pulmonary Fibrosis Drug Product Overview
Table 78. Genentech, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Genentech, Inc. Business Overview
Table 80. Genentech, Inc. Recent Developments
Table 81. Cipla Inc. Pulmonary Fibrosis Drug Basic Information
Table 82. Cipla Inc. Pulmonary Fibrosis Drug Product Overview
Table 83. Cipla Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Cipla Inc. Business Overview
Table 85. Cipla Inc. Recent Developments
Table 86. Biogen Pulmonary Fibrosis Drug Basic Information
Table 87. Biogen Pulmonary Fibrosis Drug Product Overview
Table 88. Biogen Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Biogen Business Overview
Table 90. Biogen Recent Developments
Table 91. Galapagos NV Pulmonary Fibrosis Drug Basic Information
Table 92. Galapagos NV Pulmonary Fibrosis Drug Product Overview
Table 93. Galapagos NV Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Galapagos NV Business Overview
Table 95. Galapagos NV Recent Developments
Table 96. Global Pulmonary Fibrosis Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Pulmonary Fibrosis Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Pulmonary Fibrosis Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Pulmonary Fibrosis Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Pulmonary Fibrosis Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Pulmonary Fibrosis Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Pulmonary Fibrosis Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Pulmonary Fibrosis Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Pulmonary Fibrosis Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Pulmonary Fibrosis Drug Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pulmonary Fibrosis Drug Market Size Comparison by Region (M USD)
Table 5. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Pulmonary Fibrosis Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 10. Global Market Pulmonary Fibrosis Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Pulmonary Fibrosis Drug Sales Sites and Area Served
Table 12. Manufacturers Pulmonary Fibrosis Drug Product Type
Table 13. Global Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pulmonary Fibrosis Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pulmonary Fibrosis Drug Market Challenges
Table 22. Global Pulmonary Fibrosis Drug Sales by Type (Kilotons)
Table 23. Global Pulmonary Fibrosis Drug Market Size by Type (M USD)
Table 24. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2019-2024)
Table 26. Global Pulmonary Fibrosis Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Pulmonary Fibrosis Drug Market Size Share by Type (2019-2024)
Table 28. Global Pulmonary Fibrosis Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Pulmonary Fibrosis Drug Sales (Kilotons) by Application
Table 30. Global Pulmonary Fibrosis Drug Market Size by Application
Table 31. Global Pulmonary Fibrosis Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2019-2024)
Table 33. Global Pulmonary Fibrosis Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Pulmonary Fibrosis Drug Market Share by Application (2019-2024)
Table 35. Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2019-2024)
Table 38. North America Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Pulmonary Fibrosis Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Pulmonary Fibrosis Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. Boehringer Ingelheim Pulmonary Fibrosis Drug Basic Information
Table 44. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Overview
Table 45. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Boehringer Ingelheim Business Overview
Table 47. Boehringer Ingelheim Pulmonary Fibrosis Drug SWOT Analysis
Table 48. Boehringer Ingelheim Recent Developments
Table 49. Roche Pulmonary Fibrosis Drug Basic Information
Table 50. Roche Pulmonary Fibrosis Drug Product Overview
Table 51. Roche Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Roche Business Overview
Table 53. Roche Pulmonary Fibrosis Drug SWOT Analysis
Table 54. Roche Recent Developments
Table 55. FibroGen, Inc. Pulmonary Fibrosis Drug Basic Information
Table 56. FibroGen, Inc. Pulmonary Fibrosis Drug Product Overview
Table 57. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. FibroGen, Inc. Pulmonary Fibrosis Drug SWOT Analysis
Table 59. FibroGen, Inc. Business Overview
Table 60. FibroGen, Inc. Recent Developments
Table 61. Merck and Co., Inc. Pulmonary Fibrosis Drug Basic Information
Table 62. Merck and Co., Inc. Pulmonary Fibrosis Drug Product Overview
Table 63. Merck and Co., Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Merck and Co., Inc. Business Overview
Table 65. Merck and Co., Inc. Recent Developments
Table 66. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Basic Information
Table 67. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Overview
Table 68. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Bristol-Myers Squibb Company Business Overview
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. MediciNova, Inc. Pulmonary Fibrosis Drug Basic Information
Table 72. MediciNova, Inc. Pulmonary Fibrosis Drug Product Overview
Table 73. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. MediciNova, Inc. Business Overview
Table 75. MediciNova, Inc. Recent Developments
Table 76. Genentech, Inc. Pulmonary Fibrosis Drug Basic Information
Table 77. Genentech, Inc. Pulmonary Fibrosis Drug Product Overview
Table 78. Genentech, Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Genentech, Inc. Business Overview
Table 80. Genentech, Inc. Recent Developments
Table 81. Cipla Inc. Pulmonary Fibrosis Drug Basic Information
Table 82. Cipla Inc. Pulmonary Fibrosis Drug Product Overview
Table 83. Cipla Inc. Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Cipla Inc. Business Overview
Table 85. Cipla Inc. Recent Developments
Table 86. Biogen Pulmonary Fibrosis Drug Basic Information
Table 87. Biogen Pulmonary Fibrosis Drug Product Overview
Table 88. Biogen Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Biogen Business Overview
Table 90. Biogen Recent Developments
Table 91. Galapagos NV Pulmonary Fibrosis Drug Basic Information
Table 92. Galapagos NV Pulmonary Fibrosis Drug Product Overview
Table 93. Galapagos NV Pulmonary Fibrosis Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Galapagos NV Business Overview
Table 95. Galapagos NV Recent Developments
Table 96. Global Pulmonary Fibrosis Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Pulmonary Fibrosis Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Pulmonary Fibrosis Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Pulmonary Fibrosis Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Pulmonary Fibrosis Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Pulmonary Fibrosis Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Pulmonary Fibrosis Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Pulmonary Fibrosis Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Pulmonary Fibrosis Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Pulmonary Fibrosis Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Pulmonary Fibrosis Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Pulmonary Fibrosis Drug Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Pulmonary Fibrosis Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pulmonary Fibrosis Drug Market Size (M USD), 2019-2030
Figure 5. Global Pulmonary Fibrosis Drug Market Size (M USD) (2019-2030)
Figure 6. Global Pulmonary Fibrosis Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pulmonary Fibrosis Drug Market Size by Country (M USD)
Figure 11. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2023
Figure 12. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2023
Figure 13. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pulmonary Fibrosis Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pulmonary Fibrosis Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pulmonary Fibrosis Drug Market Share by Type
Figure 18. Sales Market Share of Pulmonary Fibrosis Drug by Type (2019-2024)
Figure 19. Sales Market Share of Pulmonary Fibrosis Drug by Type in 2023
Figure 20. Market Size Share of Pulmonary Fibrosis Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Pulmonary Fibrosis Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pulmonary Fibrosis Drug Market Share by Application
Figure 24. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Pulmonary Fibrosis Drug Sales Market Share by Application in 2023
Figure 26. Global Pulmonary Fibrosis Drug Market Share by Application (2019-2024)
Figure 27. Global Pulmonary Fibrosis Drug Market Share by Application in 2023
Figure 28. Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 32. U.S. Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Pulmonary Fibrosis Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Pulmonary Fibrosis Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 37. Germany Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region in 2023
Figure 44. China Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 51. Brazil Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Pulmonary Fibrosis Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Pulmonary Fibrosis Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Pulmonary Fibrosis Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Pulmonary Fibrosis Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Pulmonary Fibrosis Drug Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Pulmonary Fibrosis Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pulmonary Fibrosis Drug Market Size (M USD), 2019-2030
Figure 5. Global Pulmonary Fibrosis Drug Market Size (M USD) (2019-2030)
Figure 6. Global Pulmonary Fibrosis Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pulmonary Fibrosis Drug Market Size by Country (M USD)
Figure 11. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2023
Figure 12. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2023
Figure 13. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pulmonary Fibrosis Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pulmonary Fibrosis Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pulmonary Fibrosis Drug Market Share by Type
Figure 18. Sales Market Share of Pulmonary Fibrosis Drug by Type (2019-2024)
Figure 19. Sales Market Share of Pulmonary Fibrosis Drug by Type in 2023
Figure 20. Market Size Share of Pulmonary Fibrosis Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Pulmonary Fibrosis Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pulmonary Fibrosis Drug Market Share by Application
Figure 24. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Pulmonary Fibrosis Drug Sales Market Share by Application in 2023
Figure 26. Global Pulmonary Fibrosis Drug Market Share by Application (2019-2024)
Figure 27. Global Pulmonary Fibrosis Drug Market Share by Application in 2023
Figure 28. Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 32. U.S. Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Pulmonary Fibrosis Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Pulmonary Fibrosis Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 37. Germany Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region in 2023
Figure 44. China Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Pulmonary Fibrosis Drug Sales Market Share by Country in 2023
Figure 51. Brazil Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Pulmonary Fibrosis Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Pulmonary Fibrosis Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Pulmonary Fibrosis Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Pulmonary Fibrosis Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Pulmonary Fibrosis Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Pulmonary Fibrosis Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Pulmonary Fibrosis Drug Market Share Forecast by Application (2025-2030)
